Qifangfeixian granules for connective tissue disease lung scarring
Part of Lungs & breathing clinical trials.
This trial tests a Chinese herbal medicine called Qifangfeixian granules for people with lung scarring (interstitial lung disease) related to connective tissue diseases (like lupus or scleroderma). It compares the medicine to a placebo to see if it helps improve breathing and lung function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a connective tissue disease (like lupus, scleroderma, rheumatoid arthritis, or similar) and lung scarring (interstitial lung disease) OR you have lung scarring without a clear connective tissue disease diagnosis but with certain signs or blood markers.
- Your liver and kidney function are within safe limits (no severe liver disease, and creatinine clearance above 30 mL/min).
- You are not pregnant, breastfeeding, or planning to become pregnant during the trial.
- You have not taken any other experimental drugs in the past month (or 6 half-lives, whichever is longer).
- You do not have severe pulmonary hypertension, unstable heart disease, or other major health issues that would interfere with the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a combination of three drugs (azithromycin, hydroxychloroquine, and prednisone) can help people with a genetic form of lung scarring. The goal is to see if these medicines calm the immune system and slow down the disease.
This study helps doctors identify early signs of lung scarring (fibrosis) in patients with autoimmune diseases like scleroderma, rheumatoid arthritis, and Sjögren's syndrome. By catching this early, researchers hope to better understand and treat these complications.
This Phase 2 study tests whether mycophenolate mofetil (MMF) can slow or improve early, mild lung scarring in people with systemic sclerosis. It’s meant for systemic sclerosis patients who have lung involvement on a CT scan but still have good breathing test results.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
This trial tests how well a CT scan and lung function tests can measure interstitial lung disease (ILD), which is long-term scarring or inflammation in the lungs. It may help doctors use these images and tests more accurately to track ILD.
This trial tests efzofitimod to see if it can improve or slow lung disease caused by systemic sclerosis (scleroderma), and to check safety and side effects. It focuses on people with relatively early disease and measurable lung involvement on lung scans.
Hear when a new Interstitial Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.